Q-omics provides the consensus-scored CDCA4P3 profile across patient tissues and cancer cell-line models. CDCA4P3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CDCA4P3 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, CDCA4P3 RNA expression shows 6,488 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight KIRC, HNSC, and LIHC as cancer lineages where CDCA4P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDCA4P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDCA4P3 survival associations across molecular data types. CDCA4P3 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDCA4P3 RNA expression–survival associations across cancer types. High CDCA4P3 expression shows unfavorable associations in KIRC, BRCA, TGCT, THCA, LIHC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CDCA4P3 RNA expression.
This table summarizes CDCA4P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CDCA4P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDCA4P3 shows higher tumor expression in HNSC, KICH, LUSC, LUAD and STAD. The HNSC box plot shows higher CDCA4P3 RNA expression in tumor versus normal tissue (log2 FC = +0.023, t-test p = .015).
This table shows molecular features associated with CDCA4P3 in patient tissues and cancer cell lines. In patient samples, CDCA4P3 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
